Silas Inman

The FDA has granted a priority review designation to rociletinib for patients with EGFR T790M-mutant metastatic non–small cell lung cancer following prior administration of an EGFR TKI.

The FDA has granted a priority review designation to eribulin mesylate as a treatment for patients with soft tissue sarcoma following an anthracycline and at least one other regimen.

Treatment with telotristat etiprate reduced the average number of daily bowel movements by up to 35% for patients with carcinoid syndrome that was not adequately controlled by a somatostatin analog.

Treatment with nivolumab reduced the risk of death by 28% compared with docetaxel for patients with previously treated nonsquamous non–small cell lung cancer.

The combination of dabrafenib plus trametinib improved overall survival by 7.6 months compared with single-agent vemurafenib in patients with unresectable or metastatic BRAFV600E/K-mutant melanoma.

The final analysis of phase III data for trabectedin were consistent with interim results by showing a lack of improvement for the primary endpoint of overall survival in patients with advanced soft tissue sarcoma.

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab plus ipilimumab in previously untreated patients with advanced melanoma.

Second-line treatment with cabozantinib reduced the risk of progression or death by 42% compared with everolimus in patients with advanced renal cell carcinoma.

The FDA has granted a priority review designation to ofatumumab as a maintenance therapy for patients with relapsed chronic lymphocytic leukemia following a response to second- or third-line therapy.

The FDA has granted a priority review designation to carfilzomib in combination with dexamethasone for patients with relapsed multiple myeloma following prior treatment with at least one therapy.

The USPSTF has issued a draft guideline recommending the use of low-dose aspirin for the prevention of colorectal cancer and cardiovascular disease in adults aged 50 to 59 years.

Trabectedin demonstrated superior disease control compared with dacarbazine in heavily pretreated patients with advanced soft tissue sarcoma.

Long-term aspirin use significantly lowered the risk of developing colorectal cancer in Lynch syndrome carriers while ameliorating the added risk associated with obesity.

A supplemental new drug application has been submitted for the BTK inhibitor ibrutinib (Imbruvica) as a therapy for treatment-naive patients with chronic lymphocytic leukemia who are over the age of 65.

Treatment with the second-generation HER2/EGFR-targeted TKI neratinib resulted in a partial response and dramatic improvement in functional status for a patient with HER2-mutated breast cancer.

Coexisting driver mutations in EGFR-mutant non–small cell lung cancer could potentially contribute to primary resistance to EGFR-targeted therapy.

The FDA has granted a priority review designation to the oral proteasome inhibitor ixazomib in combination with lenalidomide and dexamethasone as a treatment for patients with relapsed and/or refractory multiple myeloma.

Treatment with the PD-1 inhibitor nivolumab demonstrated a 32% reduction in the risk of death compared with docetaxel for patients with previously treated squamous non–small cell lung cancer.

Overregulation of new drug development has driven up the cost of care and resulted in significant loss of human life by delaying the approval of effective medications.

The FDA has assigned a priority review designation to daratumumab for heavily pretreated patients with multiple myeloma.

The European Commission has approved panobinostat in combination with bortezomib and dexamethasone for adult patients with relapsed/refractory multiple myeloma following prior treatment with bortezomib and an immunomodulatory agent.

The telomerase inhibitor imetelstat has shown encouraging signs of clinical activity in patients with myelofibrosis and essential thrombocythemia.

The first FDA-approved biosimilar, Zarxio, is now available for patients in the United States, following a series of lawsuits and court decisions.

The FDA has approved aprepitant capsules in combination with other antiemetic agents for the prevention of acute and delayed nausea and vomiting in patients aged 12 to 17 and for those under the age of 12 who weigh at least 30 kg who are receiving chemotherapy.

The European Commission has approved eltrombopag as a treatment for adult patients with severe aplastic anemia who are refractory to immunosuppressive therapy or are heavily pretreated and not suitable for hematopoietic stem cell transplant.

ASCO has updated their clinical practice guideline for the treatment of patients with stage IV non-small cell lung cancer, placing greater emphasis on the selection of targeted therapies.

The FDA has assigned a priority review designation to the intravesical immunotherapy MCNA as a treatment for patients with high-risk non-muscle invasive bladder cancer following first-line bacillus Calmette-Guerin therapy.

Patients with HER2-positive breast cancer that was ≤2 cm experienced a substantial improvement in disease-free and overall survival when treated with adjuvant trastuzumab.

Findings from a second phase II clinical trial have demonstrated impressive signs of clinical activity with the anti-CD38 monoclonal antibody daratumumab as a monotherapy for patients with heavily pretreated multiple myelom.

The alpha particle–emitting radiopharmaceutical radium-223 (Xofigo) is set to expand beyond prostate cancer, given the agent's potent efficacy and mild toxicity profile for patients with osteoblastic metastases.